Group One Trading’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.27M | Buy |
363,000
+171,700
| +90% | +$549K | ﹤0.01% | 2479 |
|
|
2025
Q4 | $522K | Buy |
191,300
+60,400
| +46% | +$140K | ﹤0.01% | 3467 |
|
|
2025
Q3 | $284K | Buy |
130,900
+17,600
| +16% | +$41.6K | ﹤0.01% | 4279 |
|
|
2025
Q2 | $195K | Sell |
113,300
-104,800
| -48% | -$261K | ﹤0.01% | 4369 |
|
|
2025
Q1 | $726K | Sell |
218,100
-717,800
| -77% | -$3.7M | ﹤0.01% | 2748 |
|
|
2024
Q4 | $6.93M | Buy |
935,900
+407,500
| +77% | +$3.78M | 0.02% | 925 |
|
|
2024
Q3 | $4.96M | Buy |
528,400
+261,900
| +98% | +$2.48M | 0.01% | 1015 |
|
|
2024
Q2 | $2.14M | Buy |
266,500
+24,200
| +10% | +$259K | 0.01% | 1400 |
|
|
2024
Q1 | $3.59M | Sell |
242,300
-62,200
| -20% | -$724K | 0.01% | 1049 |
|
|
2023
Q4 | $2.48M | Sell |
304,500
-170,700
| -36% | -$893K | 0.01% | 1690 |
|
|
2023
Q3 | $2.16M | Buy |
475,200
+348,500
| +275% | +$2.28M | 0.01% | 1583 |
|
|
2023
Q2 | $892K | Buy |
126,700
+78,900
| +165% | +$565K | ﹤0.01% | 2458 |
|
|
2023
Q1 | $292K | Sell |
47,800
-168,800
| -78% | -$1.16M | ﹤0.01% | 3311 |
|
|
2022
Q4 | $1.38M | Buy |
216,600
+208,500
| +2,574% | +$1.63M | ﹤0.01% | 2143 |
|
|
2022
Q3 | $78K | Sell |
8,100
-2,000
| -20% | -$23.1K | ﹤0.01% | 5013 |
|
|
2022
Q2 | $112K | Sell |
10,100
-17,900
| -64% | -$235K | ﹤0.01% | 4872 |
|
|
2022
Q1 | $466K | Sell |
28,000
-58,100
| -67% | -$899K | ﹤0.01% | 3891 |
|
|
2021
Q4 | $1.64M | Buy |
86,100
+5,400
| +7% | +$119K | ﹤0.01% | 2817 |
|
|
2021
Q3 | $1.99M | Sell |
80,700
-43,500
| -35% | -$1.02M | ﹤0.01% | 2657 |
|
|
2021
Q2 | $3.23M | Buy |
124,200
+99,900
| +411% | +$2.6M | ﹤0.01% | 2152 |
|
|
2021
Q1 | $769K | Sell |
24,300
-32,100
| -57% | -$1.33M | ﹤0.01% | 3537 |
|
|
2020
Q4 | $2.62M | Sell |
56,400
-3,700
| -6% | -$147K | ﹤0.01% | 1815 |
|
|
2020
Q3 | $1.98M | Sell |
60,100
-63,700
| -51% | -$1.95M | 0.01% | 1609 |
|
|
2020
Q2 | $3.4M | Buy |
123,800
+27,600
| +29% | +$907K | 0.02% | 1074 |
|
|
2020
Q1 | $2.88M | Buy |
96,200
+60,600
| +170% | +$1.61M | 0.02% | 814 |
|
|
2019
Q4 | $985K | Buy |
35,600
+24,700
| +227% | +$562K | 0.01% | 1890 |
|
|
2019
Q3 | $198K | Buy |
10,900
+800
| +8% | +$17.7K | ﹤0.01% | 3086 |
|
|
2019
Q2 | $248K | Buy |
+10,100
| New | +$152K | ﹤0.01% | 2693 |
|
|
2019
Q1 | – | Sell |
-15,700
| Closed | -$139K | – | 5063 |
|
|
2018
Q4 | $139K | Buy |
+15,700
| New | +$151K | ﹤0.01% | 2952 |
|
|
2018
Q3 | – | Sell |
-21,800
| Closed | -$279K | – | 5382 |
|
|
2018
Q2 | $279K | Buy |
21,800
+7,500
| +52% | +$110K | ﹤0.01% | 2777 |
|
|
2018
Q1 | $242K | Buy |
+14,300
| New | +$217K | ﹤0.01% | 2632 |
|
|
2017
Q3 | – | Sell |
-5,000
| Closed | -$37K | – | 4978 |
|
|
2017
Q2 | $37K | Buy |
+5,000
| New | +$31.8K | ﹤0.01% | 3650 |
|
|
2017
Q1 | – | Sell |
-27,000
| Closed | -$188K | – | 4799 |
|
|
2016
Q4 | $188K | Sell |
27,000
-11,000
| -29% | -$75.7K | ﹤0.01% | 2472 |
|
|
2016
Q3 | $313K | Buy |
38,000
+3,900
| +11% | +$33K | ﹤0.01% | 2163 |
|
|
2016
Q2 | $276K | Sell |
34,100
-13,200
| -28% | -$82.9K | ﹤0.01% | 2182 |
|
|
2016
Q1 | $240K | Buy |
47,300
+45,000
| +1,957% | +$246K | ﹤0.01% | 2204 |
|
|
2015
Q4 | $18K | Sell |
2,300
-52,700
| -96% | -$366K | ﹤0.01% | 3961 |
|
|
2015
Q3 | $317K | Buy |
55,000
+20,000
| +57% | +$156K | ﹤0.01% | 2156 |
|
|
2015
Q2 | $321K | Buy |
+35,000
| New | +$391K | ﹤0.01% | 2168 |
|
Other funds holding IOVA
MFM
VCM
VPM
ICM
Group One Trading's IOVA Position: Q1 2026 in Review
Group One Trading increased its Iovance Biotherapeutics (IOVA) stake by 253% in Q1 2026, buying an estimated $1.37M and bringing the position to 595,756 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2035.
Group One Trading first reported a position in IOVA in Q2 2015 and has held it in 33 quarters since. The position peaked at $12.6M in Q4 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.
- Group One Trading held 595,756 shares of Iovance Biotherapeutics worth $2.09M as of Q1 2026.
- Group One Trading bought 427,079 Iovance Biotherapeutics shares in Q1 2026, an estimated $1.37M.
- Iovance Biotherapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2035 holding.
- Group One Trading first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 33 quarters since.
- Group One Trading's Iovance Biotherapeutics position peaked at $12.6M in Q4 2024.
- 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.